Condensed Consolidated Interim Statements of Comprehensive Loss - USD ($) |
3 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|||
| OPERATING EXPENSES | ||||||
| Consulting | $ 309,945 | $ 242,385 | $ 441,021 | $ 660,914 | ||
| Depreciation | 2,595 | 2,234 | 9,059 | 8,114 | ||
| Foreign exchange | (6,133) | 23,031 | (17,650) | 3,600 | ||
| Office and administrative | 60,987 | 35,950 | 189,813 | 201,327 | ||
| Investor relations | 76,837 | 61,193 | 121,126 | 617,053 | ||
| Professional fees | 144,908 | 139,760 | 445,158 | 605,099 | ||
| Rent | 2,194 | 20,845 | 20,898 | 181,666 | ||
| Research and development | 29,983 | 87,696 | 123,915 | 1,111,562 | ||
| Share-based compensation | 90,242 | 99,586 | 571,210 | 401,869 | ||
| Shareholder and regulatory | 2,308 | 3,373 | 337,878 | 95,037 | ||
| Travel and entertainment | 1,075 | 4,643 | 13,426 | 189,937 | ||
| Wages and salaries | 169,665 | 264,020 | 1,071,867 | 1,042,968 | ||
| Operating loss | (884,606) | (984,716) | (3,327,721) | (5,119,146) | ||
| OTHER INCOME | ||||||
| SR&ED tax incentive income | (106,195) | |||||
| Net loss | (884,606) | (984,716) | (3,221,526) | (5,119,146) | ||
| Dividend paid to preferred shareholders | 948,064 | 488,416 | ||||
| Net loss attributable to common shareholders | (884,606) | (984,716) | (4,169,590) | (5,607,562) | ||
| Other comprehensive income (loss) | ||||||
| Foreign currency translation | 13,034 | (197,488) | (45,856) | 154,010 | ||
| Comprehensive loss attributable to common shareholders | $ (871,572) | $ (1,182,204) | $ (4,215,446) | $ (5,453,552) | ||
| Basic and diluted net loss attributed to common share* | [1] | $ (0.10) | $ (0.13) | $ (0.53) | $ (0.67) | |
| Weighted average number of common shares outstanding - basic and diluted* | [1] | 8,442,284 | 7,727,428 | 7,907,233 | 8,331,330 | |
| ||||||
| X | ||||||||||
- Definition Consulting No definition available.
|
| X | ||||||||||
- Definition Foreign exchange No definition available.
|
| X | ||||||||||
- Definition Investor relations No definition available.
|
| X | ||||||||||
- Definition Scientific research and experimental development tax incentive income. No definition available.
|
| X | ||||||||||
- Definition Shareholder and regulatory No definition available.
|
| X | ||||||||||
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for employee benefit and equity-based compensation. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line. No definition available.
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount after tax of other comprehensive income (loss) attributable to parent entity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Expenses incurred for travel and entertainment during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|